Share on StockTwits
 

Equities researchers at Barclays boosted their target price on shares of Charles River Laboratories International (NYSE:CRL) from $41.00 to $55.00 in a research report issued on Thursday, AR Network reports. The firm currently has an “equal weight” rating on the stock. Barclays’ price target would suggest a potential downside of 3.39% from the stock’s previous close.

Shares of Charles River Laboratories International (NYSE:CRL) traded up 1.77% during mid-day trading on Thursday, hitting $58.60. 268,579 shares of the company’s stock traded hands. Charles River Laboratories International has a 1-year low of $39.25 and a 1-year high of $59.57. The stock’s 50-day moving average is $56.50 and its 200-day moving average is $50.53. The company has a market cap of $2.820 billion and a price-to-earnings ratio of 27.29.

Charles River Laboratories International (NYSE:CRL) last released its earnings data on Wednesday, February 12th. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.68 by $0.05. The company had revenue of $289.20 million for the quarter, compared to the consensus estimate of $289.56 million. During the same quarter in the prior year, the company posted $0.64 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Analysts expect that Charles River Laboratories International will post $3.09 EPS for the current fiscal year.

CRL has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Charles River Laboratories International from $64.00 to $67.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Sterne Agee raised their price target on shares of Charles River Laboratories International from $60.00 to $71.00 in a research note on Monday, January 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $50.96.

Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.